eligibility_summary
Eligible: adults (≥18) with classical CD30+ HL, stage I–II FDG-avid by PET/CT, bulky nodes ≥7 cm, ECOG ≤2, contraception required. Exclude: prior HL therapy, EF <50%, platelets ≤75k, Hb ≤7, ANC ≤1.0k, CrCl <30, high LFTs/bilirubin, ≥grade 2 neuropathy, pregnancy/breastfeeding, active HBV/HCV, recent active malignancy, autoimmune needing systemic immunosuppression, other serious illness. HIV allowed on HAART ≥12 wks, avoid zidovudine, ritonavir/cobicistat, strong CYP3 inhibitors.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06377566: Single-arm phase II trial in newly diagnosed, early-stage bulky classical Hodgkin lymphoma testing BV-AVD with PET/MTV-guided adaptation. Drugs/interventions and mechanisms: - Brentuximab vedotin (ADC): anti-CD30 monoclonal antibody delivering MMAE, internalizes into CD30+ cells to disrupt microtubules. - Doxorubicin (anthracycline): topoisomerase II inhibitor/DNA intercalator, generates ROS. - Vinblastine (vinca alkaloid): inhibits microtubule assembly, arrests mitosis. - Dacarbazine (alkylating agent): methylates DNA, impairs replication. - FDG-PET/CT to adapt therapy, some cohorts may receive radiation (induces DNA double-strand breaks). Additional listed agents: pembrolizumab (anti-PD-1 checkpoint antibody), gemcitabine (nucleoside antimetabolite inhibiting DNA synthesis), vinorelbine (vinca microtubule inhibitor). Targets/pathways: CD30 on Reed-Sternberg cells, PD-1/PD-L1 axis, DNA replication/repair, mitotic spindle.